FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334626807> ?p ?o ?g. }

• W2334626807 abstract "Background: Previous studies have demonstrated that 5α-reductase inhibitors (5-ARIs) finasteride and dutasteride decrease overall prostate cancer risk, while the proportion of high risk tumors may be increased. We compared risk of biochemical recurrence and mortality after radical prostatectomy between users of 5-ARIs, alpha-blockers and medication non-users Materials and Methods: A total of men 1,315 men who underwent radical prostatectomy at the Tampere University Hospital during 1995–2009 were included in the study cohort. Post-operatively, men were followed at six month intervals during the first postoperative year and yearly afterwards. Serum PSA was measured at each visit. Biochemical relapse was defined as PSA becoming detectable after the operation. Information on causes of death was obtained from the Finnish Cancer Registry. Data on medication purchases during 1995–2009 was obtained from national prescription database. Cox proportional regression was used to analyze hazard ratios (HRs) and 95% confidence intervals (95% CI) of biochemical relapse and death. Results: A total of 117 men had used finasteride or dutasteride, while 372 had used tamsulosin or alfuzosin. During the follow-up 424 men had a biochemical relapse, while 124 died, of which 22 due to prostate cancer. The median follow-up time until biochemical relapse was 3.17 years and until death 5.08 years. Pathological T-stage and tumor Gleason score among users of either drug group did not significantly vary from non-users. However, 5-ARI and alpha-blocker users had more often local lymph node metastases and positive surgical margins. Prediagnostic PSA, Gleason grade, pathological T-stage and marginal positivity were all independent predictors of biochemical recurrence. Risk of biochemical relapse was comparable to non-users among 5–ARI users (HR 1.38; 95% CI 0.86–2.19), but elevated among alpha-blocker users (HR 1.71; 95% CI 1.31–2.25). However, this risk increase was only observed when alpha-blockers were being used after the surgery. Overall mortality and prostate cancer-specific mortality did not differ by medication usage. Conclusions: Use of finasteride or dutasteride was not associated with prostate cancer grade in this population, although the users had more often local lymph node metastases and positive surgical margins. Nevertheless, the risk of biochemical recurrence and prostate cancer mortality were not affected by 5-ARI use. Our finding of increased risk of biochemical recurrence among alpha-blocker users likely reflects treatment of symptoms of aggressive prostate cancer with alpha-blockers. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A97." @default.
• W2334626807 created "2016-06-24" @default.
• W2334626807 creator A5011425417 @default.
• W2334626807 creator A5073365583 @default.
• W2334626807 date "2011-10-01" @default.
• W2334626807 modified "2023-09-27" @default.
• W2334626807 title "Abstract A97: Risk of biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers" @default.
• W2334626807 doi "https://doi.org/10.1158/1940-6207.prev-11-a97" @default.
• W2334626807 hasPublicationYear "2011" @default.
• W2334626807 type Work @default.
• W2334626807 sameAs 2334626807 @default.
• W2334626807 citedByCount "0" @default.
• W2334626807 crossrefType "proceedings-article" @default.
• W2334626807 hasAuthorship W2334626807A5011425417 @default.
• W2334626807 hasAuthorship W2334626807A5073365583 @default.
• W2334626807 hasConcept C121608353 @default.
• W2334626807 hasConcept C126322002 @default.
• W2334626807 hasConcept C126894567 @default.
• W2334626807 hasConcept C207103383 @default.
• W2334626807 hasConcept C2775874879 @default.
• W2334626807 hasConcept C2776235491 @default.
• W2334626807 hasConcept C2777008409 @default.
• W2334626807 hasConcept C2777562237 @default.
• W2334626807 hasConcept C2778878792 @default.
• W2334626807 hasConcept C2779466945 @default.
• W2334626807 hasConcept C2780192828 @default.
• W2334626807 hasConcept C2780542891 @default.
• W2334626807 hasConcept C2910366748 @default.
• W2334626807 hasConcept C29456083 @default.
• W2334626807 hasConcept C44249647 @default.
• W2334626807 hasConcept C50382708 @default.
• W2334626807 hasConcept C71924100 @default.
• W2334626807 hasConceptScore W2334626807C121608353 @default.
• W2334626807 hasConceptScore W2334626807C126322002 @default.
• W2334626807 hasConceptScore W2334626807C126894567 @default.
• W2334626807 hasConceptScore W2334626807C207103383 @default.
• W2334626807 hasConceptScore W2334626807C2775874879 @default.
• W2334626807 hasConceptScore W2334626807C2776235491 @default.
• W2334626807 hasConceptScore W2334626807C2777008409 @default.
• W2334626807 hasConceptScore W2334626807C2777562237 @default.
• W2334626807 hasConceptScore W2334626807C2778878792 @default.
• W2334626807 hasConceptScore W2334626807C2779466945 @default.
• W2334626807 hasConceptScore W2334626807C2780192828 @default.
• W2334626807 hasConceptScore W2334626807C2780542891 @default.
• W2334626807 hasConceptScore W2334626807C2910366748 @default.
• W2334626807 hasConceptScore W2334626807C29456083 @default.
• W2334626807 hasConceptScore W2334626807C44249647 @default.
• W2334626807 hasConceptScore W2334626807C50382708 @default.
• W2334626807 hasConceptScore W2334626807C71924100 @default.
• W2334626807 hasLocation W23346268071 @default.
• W2334626807 hasOpenAccess W2334626807 @default.
• W2334626807 hasPrimaryLocation W23346268071 @default.
• W2334626807 isParatext "false" @default.
• W2334626807 isRetracted "false" @default.
• W2334626807 magId "2334626807" @default.
• W2334626807 workType "article" @default.